Royalty Pharma PLC (RPRX) Actualités

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 425 - Prospectuses and communications, business combinations

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Form 8-K - Current report

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting...

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management...

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board...

Form 8-K - Current report

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken...

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...